25 May 2013
Keywords: Ipsen, Taspoglutide, Roche, Diabetes, Financial results 2010
Article | 03 February 2011
French drugmaker Ipsen (Euronext: IPN) suffered a significant setback yesterday, when Swiss major Roche (ROG: VX) informed the group of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
3 February 2011
24 May 2013
© 2013 thepharmaletter.com